Monitor CMS compliance processes and future regulatory communications; while no revenue impact is expected, investors should assess potential risks around administrative dependencies in reimbursement workflows.
NVCR drugs
NVCR drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 25 $14.99entry
- T+1 · 9mo ago −8.27%α −7.73% · $13.75
- T+5 · 9mo ago −10.47%α −9.37% · $13.42
- T+20 · 8mo ago −22.55%α −17.31% · $11.61
- T+60 · 6mo ago +18.41%α +11.46% · $17.75
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
NovoCure announced that CMS rescinded the prior revocation of its Medicare billing privileges, reinstating them retroactively to December 17, 2025. The revocation was due to an administrative issue, not a substantive failure, and the company continued patient services during the period, expecting no revenue impact.
Key Facts
- CMS revoked NovoCure's Medicare billing privileges retroactive to December 17, 2025, due to an administrative process issue with triannual re-validation.
- On February 24, 2026, CMS rescinded the revocation and reinstated billing privileges retroactively to December 17, 2025.
- The company continued providing services to existing and new patients during the period of ineligibility.
- NovoCure believes there will be no impact on its ability to recognize revenue for services provided during the lapse.
Financial Impact
No expected financial impact; revenue recognition expected to continue uninterrupted due to retroactive reinstatement.
Risk Factors
- Potential delays in collections despite retroactive reinstatement.
- Reputational or operational risk if similar administrative issues recur.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001645113-26-000013 |
| Document: 0001645113-26-000013-index-headers.html | 0001645113-26-000013 |
| Document: 0001645113-26-000013-index.html | 0001645113-26-000013 |
| Document: 0001645113-26-000013.txt | 0001645113-26-000013 |
Track record
20 reports on NVCR
5 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +19.75% at T+20 after the Feb 27, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $11.83 to $11.30 Now $11.30 −4.48% ▼ −4.48% −2.57% vs SPY
- Nov 9, 20267d ago SC 13G/A Neutral 3/10 Entry $11.81 to $11.99 Now $11.30 −4.32% ▲ +1.52% +0.21% vs SPY
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $11.81 to $11.99 Now $11.30 −4.32% ▲ +1.52% +0.21% vs SPY
- Nov 9, 20267d ago 8-K Bearish 6/10 Entry $12.53 to $11.81 Now $11.30 +9.82% ▲ +5.75% +5.38% vs SPY
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $13.11 to $13.15 Now $11.30 −13.81% ▲ +0.31% +2.08% vs SPY
- Oct 1, 20266w ago 8-K Bullish 6/10 Entry $15.92 to $14.94 Now $11.30 −29.02% ▼ −6.16% −6.90% vs SPY
- Sep 9, 20269w ago 8-K Neutral 2/10 Entry $15.63 to $15.35 Now $11.30 −27.70% ▼ −1.79% −1.19% vs SPY
- Sep 1, 202610w ago 8-K Neutral 3/10 Entry $17.38 to $17.83 Now $11.30 −34.98% ▲ +2.59% +2.15% vs SPY
- Jul 23, 202616w ago 8-K Bullish 7/10 Entry $19.99 to $17.65 Now $11.30 −43.47% ▼ −11.71% −11.81% vs SPY
- Jun 30, 202619w ago 8-K Bullish 7/10 Entry $15.15 to $15.78 Now $11.30 −25.41% ▲ +4.16% +4.29% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers